is all in $AAPL $TSLA and $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
35% more HEAVEN!
Blockchain Indulgences! Genius.
Lovely disclaimer: "Jesus Coin is guaranteed to save all of its owners from hell (except Jews, Muslims, Hindus, Bahai, Buddhists and Sikhs)."
I love that Pistol Pete! Reminds me of the BASF campaign: "We don't make many of the things you use, we make them better!"
SRO's are off limits to investments by FDA employees and family members. It's basically a restricted stock list for the FDA. Lol too bad this restriction doesn't apply to our members of congress!
We certainly meet the criteria to be listed. If you have other "bio" penny tickers please look them up on the SRO search. I only see real companies listed.
Go $PMCB!
Well the Annual Report specifically mentions Diabetes and Malignant Ascites. I noticed the $PMCB website also lists Breast Cancer under Cancers:
http://pharmacyte.com/cancer/
Targeted chemotherapy has fewer side effects, so while I know diabetes is a more profitable line of business, I do hope they soon will have the partners and resources they need to make a push into breast cancer research.
Dr. Hidalgo, MD, PhD, is going to be our Principal Investigator and he is just incredible!
On Sept 6th $PMCB IR noted that KW was in Boston:
Renee! Sorry, I don't have PM but I really wanted to say "Hello!" and "Thank you!"
You gave me some great advice a few months back which ultimately saved me from taking a major bath.
If I can every do anything to help you please don't hesitate to ask. : )
As an investor since just Jan 2017, I have no idea who those people are and I don't care because they aren't in the annual report and neither are the words "tattoo ink". Off topic?
So maybe instead of discussing things which have absolutely no relevance to $PMCB today you could weigh in on Pepper Hamilton's sudden involvement.
I mean, you have the law firm that just got Johnson & Johnson off the hook in a massive Federal case suddenly filing our S-3. Call me crazy, but maybe that's a more relevant topic for discussion.
PMCB is paying Austrianova as per the terms of their agreements. Doesn't matter what Austrianova has in the bank, PMCB must pay what's due if it wants to continue to have a seat at the table.
High frequency/program trading. Some believe traders send signals to each other via bid/ask and size, but I think there's usually a reason for an odd size.
I recall seeing batches of $PMCB shares in 499 lots, which seems weird but when multiplied by the order price was nearly $30 exactly.
So I think that was someone tinkering with designing and developing a new program trading system- literally someone testing their trading system in a live, but low risk environment (PMCB is a fairly stable penny stock)- before using it with real money.
$EARS should have some news due in Q4 on Phase 3 AM-111 HEALOS for Acute inner ear hearing loss.
After the $PMCB S-3 was filed I started looking into the reasons other pre-clinical biotechs filed S-3.
What I found was an interesting pattern. In two cases I found S-3s filed after a partnership was announced:
April 6, 2016: http://ir.tesarobio.com/releasedetail.cfm?releaseid=963728
June 30, 2016: http://ir.tesarobio.com/secfiling.cfm?filingID=1047469-16-14088&CIK=1491576
May 18, 2016: http://ir.macrogenics.com/releasedetail.cfm?releaseid=971495
Nov 11, 2016: http://files.shareholder.com/downloads/AMDA-278VRP/5199416798x0xS1552781-16-2034/1125345/filing.pdf
And in one case I found an S-3 filed before a partnership was announced:
March 28, 2017: http://www.ligand.com/news-events/press-releases/detail/320/ligand-announces-licensing-partner-janssen-has-filed-an-ind
January 8, 2017: http://investor.ligand.com/all-sec-filings/content/0001193125-16-424831/0001193125-16-424831.pdf
Now S-3s are filed for various reasons of course, I just thought it was interesting as these are all biotechs.
It didn't take me very long to find these and I'm sure there must be dozens of other examples out there. Anyone know of other examples?
$PMCB has medical and scientific professionals with the following CURRENT associations:
Dr. Sher, Chief Medical Officer, CURRENTLY a Professor at University of Southern California’s Keck School of Medicine
Dr. Günzburg, Chief Science Officer, CURRENTLY a Professor at University of Vienna
Dr. Löhr, Chair of PMCB's Medical and Scientific Advisory Board, CURRENTLY a Professor at Karolinska Institute and CURRENTLY a Member of German Cancer Research Centre
Dr. Brandtner, Director of Diabetes Program, CURRENTLY the Head of the Bioencapsulation at the Vorarlberg Institute for Vascular Investigation and Treatment, and CURRENTLY a member of European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT)
Dr. Rabe, Director of Cannabis Program, CURRENTLY running the cannabis program at University of Northern Colorado
Dr. Abecassis, Board Member, CURRENTLY a surgeon and the director of the Transplant Center at Northwestern University Feinberg School of Medicine
Dr. Hidalgo, Advisory Board Member, CURRENTLY Director of the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC)
Dr. Hammes, Advisory Board Member, CURRENTLY a Professor at Heidelberg University
FURTHERMORE, the management team has years of experience at top pharma companies:
Mr. Liquard, Board Member, 7 years at Pfizer
Dr. Crabtree, Board Member, 7 years at Bristol-Myers Squibb
Dr. Günzburg, CSO, 7 years at Bavarian Nordic
FINALLY, between all of these professional there are HUNDREDS of published, peer reviewed scientific articles
What is most interesting to me about the S-3 is who filed it. Merrill M. Kraines is not only a Partner at Pepper Hamilton LLP, he's the Head of the Life Sciences, Technology and Emerging Growth practice areas in the New York office.
Many people may not be familiar with how corporate law firms operate, but, trust me, it's a big deal when the head of a 50+ lawyer practice group puts his stamp of approval on your SEC filing.
So, if you step back and think about it there are two possibilities here. Remember, Pepper Hamilton is (a) in the top 100 law firms in the US in terms of revenue, (b) one of the oldest law firms in the US, (c) has argued cases in front of the US Supreme Court, and (d) merged with the NJ law firm, Jamieson Moore, that traditionally represented Janssen.
The first possibility is $PMCB approached Pepper Hamilton and asked it to file the S-3. That's perfectly plausible and it means Pepper Hamilton has done their due diligence (in the truest sense of the term!) on PharmaCyte and agreed to take them on as a new client. Shareholders should take this engagement as a vote of confidence, as law firms of this caliber have ethical and liability standards that far, far outweigh the need to earn $25K in fees.
The second possibility is that another client of Pepper Hamilton has asked it to file the S-3 for $PMCB so that the other client's interests are protected. That may seem odd, but it's typical when one company is so much more powerful (for lack of a better term) than the second, smaller company. (Imagine you are the head of a $50 Billion dollar company and you are looking to work with a $50 Million dollar company. You are naturally going to have your accountants and your attorneys size up the company, you will not be relying on the smaller firm's usual accountants and lawyers.)
Generally speaking when you're doing DD, if you see a company suddenly switch accounting firms and/or law firms it could mean something is going on, especially when the company goes from having a small, local firm to a nationally-recognized firm.
mind1- There is very little point in trying to correct someone who lacks basic accounting and investment knowledge.
Since $PMCB has a market cap of $68M and $PMCB's assets are primarily its stake in, rights to, and IP related to Austrianova's IP, than obviously the market value attributed to Austrianova would be multiples of PMCB.
Technicals are looking good too!
The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.
All we need here is some news and we could see a nice move!
Prof. Günzburg is a founder of Austrianova and currently its Chairman and CTO.
As a private company, it doesn't have to publish any information on it's investments. Does it hold any $PMCB stock? I would be very, very surprised if it didn't.
Annual report.
"In September 2014, Dr. Günzburg was appointed as our Chief Scientific Officer. Dr. Günzburg was compensated by our issuing Vin-de-Bona 500,000 shares of our common stock. Dr. Günzburg is compensated in the same way and in the same amount for each succeeding year during which he serves as our Chief Scientific Officer.
Dr. Matthias Löhr, a noted European oncologist and gastroenterologist, also participates in the development of our pancreatic cancer therapy. Dr. Löhr, currently with the Karolinska Institute in Stockholm, Sweden, served as Principal Investigator of the earlier Phase 1/2 and Phase 2 clinical trials (discussed below) of the combination of CapCell® (now known as and hereinafter referred to as “Cell-in-a-Box®”) with low-dose ifosfamide in patients with advanced, inoperable pancreatic cancer. Like Dr. Günzburg and Dr. Salmons, Dr. Löhr is involved in planning and overseeing much of our planned pivotal clinical trial with respect to which we had a Pre-IND meeting with CBER in January 2017. Dr. Löhr is the Chairman of our Medical and Scientific Advisory Board (“Advisory Board”) and a consultant to us. Dr. Löhr received 500,000 shares of our common stock to serve on the Advisory Board and has received a like amount under a Professional Services Agreement with us that became effective in May 2016. He also receives fees to provide professional consulting services to us through his consulting company based upon a confidential hourly rate."
When things really start to heat up, expect to see more shares and options offered to these Principals.
I've seen no Form 4's for these people, which would be required if they had sold any of these shares.
No one can accurately predict what will happen here, but there are a few things we can keep in mind.
$PMCB owns 14.5% of Austrianova. More importantly, Principals in Austrianova have significant shares in $PMCB. $PMCB also just gained Right of First Refusal for any potential deal Austrianova brokered. We have our 2016 Binding Memo of Understanding that states PMCB will develop CiaB for cancers and that the two will share net revenues from any drugs developed by PMCB. We also have exclusive rights to diabetes development for CiaB. The two entities are strongly linked and the deals and agreements in place are for revenue sharing so both companies profit.
The other side of the equation is entirely unknown. Would any potential partner want to pay royalties or would the partner eventually want to own the technology outright?
But one thing at a time. Let's get that IND submitted!
i wonder if in my lifetime I'll see the sort of advertising depicted in Minority Report where billboards scanned your eyes and projected personalized, customized ads directly to you.
I can see by the letters you used you type with both hands over the "home keys". Or, as I like to say, classically trained! On a typewriter I hope!
I do believe we are very close and the excitement is monumental!
On Sept 6th $PMCB IR noted that KW was in Boston:
You're absolutely right, it is just stupid. I can sit here smugly looking down on Millennials for documenting their entire lives on social media, but the truth is I'm walking around with an iPhone in my pocket that is both a GPS and microphone (and with the iPhone X a 3D scanner!!!). Sophisticated hackers and certainly the government could easily remotely monitor anyone with a smart phone in their pocket or an Alexa on the mantel.
I'm like you about emails. I've typed and deleted countless messages after reading them and asking myself, "will I get fired if this gets forwarded to the wrong person?" Face to face is always best. You can see the person's reaction in real time and no paper trail.
That is a great point. Personal and Executive Assistants who are sharp quickly realize they are a proxy for their bosses and can get anything they want by dropping the boss's name!
Reminds me of the social engineering technique of walking around like you own the place and carrying a clipboard, because everyone assumes you're supposed to be there and nobody wants to look like they're out of the loop.
I imagine corporate espionage is easier in the US than anywhere else in the world.
I was so happy with my first office as it had a lock on the door and it had locking file cabinets and desk drawers. Fast forward several years and I'm standing outside my office because I misplaced my keys. Secretary walks by and offers me her key. What she knew but I didn't know is that EVERY door in the office had the exact same lock. Hundreds of doors!
Nowadays Bud Fox could pose as a IT Tech, walk up to any of those bulk HP printers next to the law partner's office and, copying the internal memory, get a copy of every document ever printed on the printer.
So what's your feeling about the iPhone fingerprint scanner and the upcoming facial scanner?
I remember getting very excited at a career day in high school because the FBI was going to be there. In the Q&A, I asked them what they had studied in college and they both said "Accounting" and I was like WTF my life is a lie!!!
This is a huge problem in corporations with draconian password rules. The gimmick in movies where the hero finds the car keys in the visor will be superseded with the hero finding the password on a Post-It Note in the desk.
Thank you very much!
Several months ago I suspected a company wasn't filing Form 4s for insider trades and, lo and behold, an officer was fired for unreported insider sales and is apparently being sued. I had reported my suspicion to the SEC's whistleblower program.
I suspect I'll never hear anything more on this matter. Is my expectation correct based on your experiences?
Can you please elaborate? If the FDA trial started it would be a matter of record. As far as I know it isn't possible to have a trial conducted in secrecy because of a NDA.
I've been looking at the structure of some of these deals and they are very shrewd. Some might even say ruthless. Of course, you'd expect nothing less when you have top law firms crafting the deals.
But to address your question, it entirely depends on the terms so we could only accurately speculate IF and WHEN a deal is announced. That's a big IF and a big WHEN and that's why pre-clinical biotechs are so speculative.
Remember, in exchange for funding and invaluable guidance, these deals are set up specifically so the large firms can either outright acquire if all goes well or simply walk away from the partnership if the trial fails.
So it's absolutely imperative that the trials are flawlessly designed. KW has said many times that they have "one chance to get it right". That makes the most sense in the context of partnerships.
No idea about the price. But I do know to get top dollar you would (a) want the pancreatic cancer indication to go flawlessly as that would validate the proof of concept and mean CiaB could get accelerated approval for other chemo drug combinations for other indications and (b) have some movement on the diabetes side.
The market will dictate share price entirely on the potential. $PMCB's market cap is where it is because we are most advanced on one indication. If that indication is approved and it looks like we have a fast track to other indications, the value multiples quickly. Diabetes is just a massive market as well. If things go well there I would be very, very surprised to see PMCB remaining independent.
I don't like to speculate on share price honestly. The analysts who are good at that have access to expensive data and have sophisticated models at their fingertips. But I can say with 100% confidence if all goes well with the IND submission the price will go up. : )
Great video! At the 11 minute mark the doctor says, essentially, chemotherapy radiation is damaging to all tissue and ideally you would apply it to just the tumor. That was 5 years ago and here we are with $PMCB trying to get a trial started where radiation would be localized using CiaB.
Cell-in-a-Box is a technology that IMO is about to shine. You have countless chemotherapy drugs that are or will soon lose exclusivity. You take cells which can produce those drugs, encapsulate the cells in CiaB, and now you have a new biologic that is market exclusive.
It gives new life to a proven drug, it gives $PMCB a chance to use CiaB in countless indications, and MOST IMPORTANTLY, it gives patients less exposure to radiation than traditional chemotherapy.
What is most interesting to me about the S-3 is who filed it. Merrill M. Kraines is not only a Partner at Pepper Hamilton LLP, he's the Head of the Life Sciences, Technology and Emerging Growth practice areas in the New York office.
Many people may not be familiar with how corporate law firms operate, but, trust me, it's a big deal when the head of a 50+ lawyer practice group puts his stamp of approval on your SEC filing.
So, if you step back and think about it there are two possibilities here. Remember, Pepper Hamilton is (a) in the top 100 law firms in the US in terms of revenue, (b) one of the oldest law firms in the US, (c) has argued cases in front of the US Supreme Court, and (d) merged with the NJ law firm, Jamieson Moore, that traditionally represented Janssen.
The first possibility is $PMCB approached Pepper Hamilton and asked it to file the S-3. That's perfectly plausible and it means Pepper Hamilton has done their due diligence (in the truest sense of the term!) on PharmaCyte and agreed to take them on as a new client. Shareholders should take this engagement as a vote of confidence, as law firms of this caliber have ethical and liability standards that far, far outweigh the need to earn $25K in fees.
The second possibility is that another client of Pepper Hamilton has asked it to file the S-3 for $PMCB so that the other client's interests are protected. That may seem odd, but it's typical when one company is so much more powerful (for lack of a better term) than the second, smaller company. (Imagine you are the head of a $50 Billion dollar company and you are looking to work with a $50 Million dollar company. You are naturally going to have your accountants and your attorneys size up the company, you will not be relying on the smaller firm's usual accountants and lawyers.)
Generally speaking when you're doing DD, if you see a company suddenly switch accounting firms and/or law firms it could mean something is going on, especially when the company goes from having a small, local firm to a nationally-recognized firm.
My first buy was 10,000 @ .15 I believe.
Anyway, I wrote "there is no underwriting agreement" and you replied about underwriters. That's two different things.
PMCB could just keep issuing stock as per its last effective registration statement. There was no need to do the S-3 to continue doing smaller offerings. The new S-3 is for a Note.
What shares? The registration statement has no underwriting agreement attached.
725K bought and 175K sold.
$PMCB Longs are not going to part with shares at these prices, not before IND is filed.
A whole host of people with lower risk tolerance won't invest until IND is actually filed, so we will continue to trade in this 5-9 range until big news drops IMO.
Go $PMCB Longs!
Everywhere I look I see encapsulation being discussed: http://news.mit.edu/2017/one-vaccine-injection-could-carry-many-doses-0914
Good time to be invested in $PMCB.
And nice trading today: 500K buys and just 60K sales so far.
Go $PMCB Longs!!!
I only made markets in ETF and those are very different from regular stocks because you interface with the issuer and not the companies directly. I also never made a market in an OTC security, but I'm sure it's really just like ECNs.
Anyway, I got into PMCB in January 2017 and I honestly haven't looked at the prior year charts very closely. I'm more interested in the future here and I think it's looking very promising!
London terror attack...